L3VLUP
ProSign in

PCVX in the 13F filings

Vaxcyte Inc · CUSIP 92243G108

Sector · Pharmaceuticals and biotechnologyTheme · Biological productsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
31 Dec 2023
the date the book describes
Filed
5 Nov 2026
latest of these filings; the earliest 12 Feb 2024
Managers listing it
9
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q3 2023 and Q4 2023; 8 listed it in both
Shares listed
34,189,676
combined, among listed positions
Reported value
$2.1bn
combined, at the quarter end

Among the 93 comparable managers: 5 buyers (opened or added shares) and 4 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.

Managers listing PCVX in Q4 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q3 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

9 of 9 holders

ActionFiling
Fidelity (FMR LLC)14,213,365$893m0.07%Added+136,3285 Nov 2026 (the filing on sec.gov)
Janus Henderson Group Ltd6,981,376$438m0.26%Trimmed-79,21214 Feb 2024 (the filing on sec.gov)
Wellington Management Group LLP4,431,920$278m0.05%Trimmed-166,79212 Feb 2024 (the filing on sec.gov)
Capital Research Global Investors3,440,107$216m0.05%Added+75,98013 Feb 2024 (the filing on sec.gov)
T. Rowe Price Associates Inc2,677,822$168munder 0.1%Added+260,17016 Feb 2024 (the filing on sec.gov)
AllianceBernstein LP1,915,047$120munder 0.1%Trimmed-28,78314 Feb 2024 (the filing on sec.gov)
Woodline Partners LP393,351$25m0.27%Added+12,73814 Feb 2024 (the filing on sec.gov)
Schonfeld Strategic Advisors LLC133,288$8.4m0.06%Trimmed-132,73314 Feb 2024 (the filing on sec.gov)
Farallon Capital Management LLC3,400$214kunder 0.1%Newnew14 Feb 2024 (the filing on sec.gov)

Largest increases and reductions, by shares

Q3 2023 to Q4 2023, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (1)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
12 in Q3 2024 to 8 in Q2 2026

Tracked managers listing it, at least.

051015202120222023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
PCVX by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20202$141mn.a.n.a.
Q3 20202$515mn.a.n.a.
Q4 20201$108mn.a.n.a.
Q1 20211$84mn.a.n.a.
Q2 20211$93mn.a.n.a.
Q3 20211$104mn.a.n.a.
Q4 20212$103mn.a.n.a.
Q1 20222$106mn.a.n.a.
Q2 20224$107mn.a.n.a.
Q3 20225$140mn.a.n.a.
Q4 202212$1.2bnn.a.n.a.
Q1 20238$978mn.a.n.a.
Q2 20238$1.6bnn.a.n.a.
Q3 20239$1.8bnn.a.n.a.
Q4 20239$2.1bn54
Q1 20249$2.7bn81
Q2 202410$3.1bn46
Q3 202412$5.1bn84
Q4 202411$3.6bn66
Q1 20256$1.8bn33
Q2 20257$969m52
Q3 20259$940m55
Q4 20259$1.8bn1318
Q1 202612$2.7bn1813
Q2 20268$2.9bn1317

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

PCVX and GILD →PCVX and AMGN →PCVX and ARGX →Choose a stock to compare with PCVX →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own PCVX, latest filings →Back to the 13F Explorer →